{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:40:43Z","timestamp":1790793643774,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":1195,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.exphem.2019.01.003","type":"journal-article","created":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T07:37:27Z","timestamp":1547624247000},"page":"61-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Modeling malignancies using induced pluripotent stem cells: from chronic myeloid leukemia to hereditary cancers"],"prefix":"10.1016","volume":"71","author":[{"given":"Ali","family":"Turhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adlen","family":"Foudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9170-397X","authenticated-orcid":false,"given":"Jin Wook","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7679-2524","authenticated-orcid":false,"given":"Christophe","family":"Desterke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Griscelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelise","family":"Bennaceur-Griscelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2019.01.003_bib0001","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","article-title":"Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors","volume":"126","author":"Takahashi","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2019.01.003_bib0002","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/embj.201387098","article-title":"iPS cells: a game changer for future medicine","volume":"33","author":"Inoue","year":"2014","journal-title":"EMBO J"},{"key":"10.1016\/j.exphem.2019.01.003_bib0003","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.exphem.2014.03.010","article-title":"Generation of induced pluripotent stem cells derived from primary and secondary myelofibrosis patient samples","volume":"42","author":"Hosoi","year":"2014","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2019.01.003_bib0004","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41375-018-0169-y","article-title":"Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells","volume":"33","author":"Tasian","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2019.01.003_bib0005","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/nbt.3178","article-title":"Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells","volume":"33","author":"Kotini","year":"2015","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.exphem.2019.01.003_bib0006","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2016.11.018","article-title":"Human AML-iPSCs reacquire leukemic properties after differentiation and model clonal variation of disease","volume":"20","author":"Chao","year":"2017","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.exphem.2019.01.003_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2017.01.009","article-title":"Stage-specific human induced pluripotent stem cells map the progression of myeloid transformation to transplantable leukemia","volume":"20","author":"Kotini","year":"2017","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.exphem.2019.01.003_bib0008","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1126\/science.959840","article-title":"The clonal evolution of tumor cell populations","volume":"194","author":"Nowell","year":"1976","journal-title":"Science"},{"key":"10.1016\/j.exphem.2019.01.003_bib0009","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1182\/blood.V73.1.248.248","article-title":"Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin","volume":"73","author":"Janssen","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2019.01.003_bib0010","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0002-9343(77)90124-3","article-title":"Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte\/macrophage","volume":"63","author":"Fialkow","year":"1977","journal-title":"Am J Med"},{"key":"10.1016\/j.exphem.2019.01.003_bib0011","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature03128","article-title":"Identification of human brain tumour initiating cells","volume":"432","author":"Singh","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2019.01.003_bib0012","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nature05349","article-title":"Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells","volume":"444","author":"Piccirillo","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2019.01.003_bib0013","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature05372","article-title":"A human colon cancer cell capable of initiating tumour growth in immunodeficient mice","volume":"445","author":"O'Brien","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2019.01.003_bib0014","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1073\/pnas.0530291100","article-title":"Prospective identification of tumorigenic breast cancer cells","volume":"100","author":"Al-Hajj","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2019.01.003_bib0015","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1038\/nm.3336","article-title":"The epigenetics of epithelial\u2013mesenchymal plasticity in cancer","volume":"19","author":"Tam","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2019.01.003_bib0016","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.stem.2008.02.009","article-title":"Module map of stem cell genes guides creation of epithelial cancer stem cells","volume":"2","author":"Wong","year":"2008","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.exphem.2019.01.003_bib0017","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/ng.127","article-title":"An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors","volume":"40","author":"Ben-Porath","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.exphem.2019.01.003_bib0018","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/ng.465","article-title":"SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas","volume":"41","author":"Bass","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.exphem.2019.01.003_bib0019","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1038\/oncsis.2014.5","article-title":"A mesenchymal glioma stem cell profile is related to clinical outcome","volume":"3","author":"Balbous","year":"2014","journal-title":"Oncogenesis"},{"key":"10.1016\/j.exphem.2019.01.003_bib0020","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/gm291","article-title":"Embryonic stem cell-specific signatures in cancer: insights into genomic regulatory networks and implications for medicine","volume":"3","author":"Kim","year":"2011","journal-title":"Genome Med"},{"key":"10.1016\/j.exphem.2019.01.003_bib0021","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ng.392","article-title":"Lin28 promotes transformation and is associated with advanced human malignancies","volume":"41","author":"Viswanathan","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.exphem.2019.01.003_bib0022","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","article-title":"EMT, CSCs, and drug resistance: the mechanistic link and clinical implications","volume":"14","author":"Shibue","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.exphem.2019.01.003_bib0023","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/nature08235","article-title":"Suppression of induced pluripotent stem cell generation by the p53-p21 pathway","volume":"460","author":"Hong","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2019.01.003_bib0024","doi-asserted-by":"crossref","first-page":"713","DOI":"10.18632\/oncotarget.333","article-title":"Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy","volume":"2","author":"Chomel","year":"2011","journal-title":"Oncotarget"},{"key":"10.1016\/j.exphem.2019.01.003_bib0025","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.exphem.2019.01.003_bib0026","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1182\/blood-2013-10-536078","article-title":"Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSCs) in chronic myeloid leukemia","volume":"123","author":"Herrmann","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2019.01.003_bib0027","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1242\/dev.128.22.4597","article-title":"Clonal analysis of differentiating embryonic stem cells reveals a hematopoietic progenitor with primitive erythroid and adult lymphoid-myeloid potential","volume":"128","author":"Perlingeiro","year":"2001","journal-title":"Development"},{"key":"10.1016\/j.exphem.2019.01.003_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.exphem.2012.12.004","article-title":"Biological effects of T315I-mutated BCR-ABL in an embryonic stem cell-derived hematopoiesis model","volume":"41","author":"Melkus","year":"2013","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2019.01.003_bib0029","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1182\/blood-2009-07-231845","article-title":"Generation of iPSCsfrom cultured human malignant cells","volume":"115","author":"Carette","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2019.01.003_bib0030","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1182\/blood-2010-07-298331","article-title":"Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells","volume":"117","author":"Hu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2019.01.003_bib0031","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1182\/blood-2011-07-367441","article-title":"Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples","volume":"119","author":"Kumano","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2019.01.003_bib0032","doi-asserted-by":"crossref","first-page":"e71596","DOI":"10.1371\/journal.pone.0071596","article-title":"Variable behavior of iPSCs derived from CML patients for response to TKI and hematopoietic differentiation","volume":"8","author":"Bedel","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2019.01.003_bib0033","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.exphem.2017.05.007","article-title":"Whole-genome analysis reveals unexpected dynamics of mutant subclone development in a patient with JAK2-V617F-positive chronic myeloid leukemia","volume":"53","author":"Sloma","year":"2017","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2019.01.003_bib0034","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.scr.2015.10.015","article-title":"Discovery of survival factor for primitive chronic myeloid leukemia cells using induced pluripotent stem cells","volume":"15","author":"Suknuntha","year":"2015","journal-title":"Stem Cell Res"},{"key":"10.1016\/j.exphem.2019.01.003_bib0035","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.stemcr.2018.01.015","article-title":"ADAM8 is an antigen of tyrosine kinase inhibitor-resistant chronic myeloid leukemia cells identified by patient-derived induced pluripotent stem cells","volume":"10","author":"Miyauchi","year":"2018","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.exphem.2019.01.003_bib0036","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2019.01.003_bib0037","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.scr.2016.08.001","article-title":"Generation of an induced pluripotent stem cell line from a patient with chronic myeloid leukemia (CML) resistant to targeted therapies","volume":"17","author":"Telliam","year":"2016","journal-title":"Stem Cell Res"},{"key":"10.1016\/j.exphem.2019.01.003_bib0038","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/mt.2013.71","article-title":"Generation of engraftable hematopoietic stem cells from induced pluripotent stem cells by way of teratoma formation","volume":"21","author":"Suzuki","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.exphem.2019.01.003_bib0039","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0200923","article-title":"Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML)","volume":"13","author":"Gentil","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2019.01.003_bib0040","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nature09871","article-title":"Copy number variation and selection during reprogramming to pluripotency","volume":"471","author":"Hussein","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2019.01.003_bib0041","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1101\/gad.1213504","article-title":"Reprogramming of a melanoma genome by nuclear transplantation","volume":"18","author":"Hochedlinger","year":"2004","journal-title":"Genes Dev"},{"key":"10.1016\/j.exphem.2019.01.003_bib0042","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/j.celrep.2013.05.036","article-title":"An iPSC line from human pancreatic ductal adenocarcinoma undergoes early to invasive stages of pancreatic cancer progression","volume":"3","author":"Kim","year":"2013","journal-title":"Cell Rep"},{"key":"10.1016\/j.exphem.2019.01.003_bib0043","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.cell.2014.02.030","article-title":"Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells","volume":"157","author":"Suv\u00e0","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2019.01.003_bib0044","doi-asserted-by":"crossref","first-page":"10743","DOI":"10.1038\/ncomms10743","article-title":"Establishment of human iPSC-based models for the study and targeting of glioma initiating cells","volume":"7","author":"Sancho-Martinez","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.exphem.2019.01.003_bib0045","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.cell.2015.02.045","article-title":"Modeling familial cancer with induced pluripotent stem cells","volume":"161","author":"Lee","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2019.01.003_bib0046","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s10689-009-9240-1","article-title":"Methylation not a frequent \"second hit\" in tumors with germline BRCA mutations","volume":"8","author":"Dworkin","year":"2009","journal-title":"Fam Cancer"},{"key":"10.1016\/j.exphem.2019.01.003_bib0047","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.stemcr.2013.08.004","article-title":"Analysis of induced pluripotent stem cells from a BRCA1 mutant family","volume":"1","author":"Soyombo","year":"2013","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.exphem.2019.01.003_bib0048","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.scr.2017.09.003","article-title":"Generation of induced pluripotent stem cell (iPSCs) line from a patient with triple negative breast cancer with hereditary exon 17 deletion of BRCA1 gene","volume":"24","author":"Griscelli","year":"2017","journal-title":"Stem Cell Res"},{"key":"10.1016\/j.exphem.2019.01.003_bib0049","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1210\/jc.2013-1204","article-title":"Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update","volume":"98","author":"Wells","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.exphem.2019.01.003_bib0050","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.scr.2017.11.015","article-title":"Transcriptional landscape of a RET","volume":"26","author":"Hadoux","year":"2018","journal-title":"Stem Cell Res"},{"key":"10.1016\/j.exphem.2019.01.003_bib0051","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.scr.2017.07.022","article-title":"Generation of an induced pluripotent stem cell line from a patient with hereditary multiple endocrine neoplasia 2B (MEN2B) syndrome with \"highest risk\" RET mutation","volume":"23","author":"Bennaceur-Griscelli","year":"2017","journal-title":"Stem Cell Res"},{"key":"10.1016\/j.exphem.2019.01.003_bib0052","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/nm.4355","article-title":"Colonic organoids derived from human induced pluripotent stem cells for modeling colorectal cancer and drug testing","volume":"23","author":"Crespo","year":"2017","journal-title":"Nat Med"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X19300086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X19300086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:34:40Z","timestamp":1759566880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X19300086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":52,"alternative-id":["S0301472X19300086"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2019.01.003","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modeling malignancies using induced pluripotent stem cells: from chronic myeloid leukemia to hereditary cancers","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2019.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc. on behalf of ISEH -- Society for Hematology and Stem Cells.","name":"copyright","label":"Copyright"}]}}